Amyloid-beta Toxic Oligomers ELISA
- Regulatory Status
- RUO
- Kit size
- 12x8
- Method
- ELISA
- Incubation time
- 1x18h, 1x1h, 1x30min
- Standard range
- 3.13 - 200 pg/mL
- Specimen / Volumes
- 50 µL CSF
- Substrate / isotope
- TMB 450 nm
| instructions for use |
|---|
"Original article #27709
Oligomerization of Amyloid-β (Amyloid-beta) 42 is considered as an early event in Alzheimer ’s disease (AD). Irie et al. have proposed their hypothesis from the study of systematic proline scanning and solid-state NMR that an Amyloid-beta conformer with a turn structure at positions 22 and 23 in aggregation of Amyloid Beta 42 has much higher toxicity and it is also easily formed to become an oligomer.
1) It has been considered that the toxic Amyloid-beta conformer is stable and easily formed to become a neurotoxic oligomer. The antibody (clone: 24B3) specifically detects a toxic Amyloid-beta conformer was established for development of the ELISA assay kit.
2) This kit can measure selectively putative Amyloid-beta Oligomer in CSF.
Separate control set available on request
For concrete data please consult the Instruction for Use in the download box on the top right side.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.